Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 1;26(9):1151-9.
doi: 10.1097/QAD.0b013e328352d135.

Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants

George K Siberry  1 , Paige L Williams, Hermann Mendez, George R Seage 3rd, Denise L Jacobson, Rohan Hazra, Kenneth C Rich, Raymond Griner, Katherine Tassiopoulos, Deborah Kacanek, Lynne M Mofenson, Tracie Miller, Linda A DiMeglio, D Heather Watts; Pediatric HIV/AIDS Cohort Study (PHACS)
Collaborators, Affiliations

Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants

George K Siberry et al. AIDS. .

Abstract

Objective: To evaluate the association of tenofovir disoproxil fumarate (TDF) use during pregnancy with early growth parameters in HIV-exposed, uninfected (HEU) infants.

Design: US-based prospective cohort study of HEU children to examine potential adverse effects of prenatal TDF exposure.

Methods: We evaluated the association of maternal TDF use during pregnancy with small for gestational age (SGA); low birth weight (LBW, <2.5 kg); weight-for-age z-scores (WAZ), length-for-age z-scores (LAZ), and head circumference-for-age (HCAZ) z-scores at newborn visit; and LAZ, HCAZ, and WAZ at age 1 year. Logistic regression models for LBW and SGA were fit, adjusting for maternal and sociodemographic factors. Adjusted linear regression models were used to evaluate LAZ, WAZ, and HCAZ by TDF exposure.

Results: Of 2029 enrolled children with maternal antiretroviral information, TDF was used by 449 (21%) HIV-infected mothers, increasing from 14% in 2003 to 43% in 2010. There was no difference between those exposed to combination regimens with vs. without TDF for SGA, LBW, and newborn LAZ and HCAZ. However, at age 1 year, infants exposed to combination regimens with TDF had significantly lower adjusted mean LAZ and HCAZ than those without TDF (LAZ: -0.17 vs. -0.03, P=0.04; HCAZ: 0.17 vs. 0.42, P=0.02).

Conclusion: TDF use during pregnancy was not associated with increased risk for LBW or SGA. The slightly lower mean LAZ and HCAZ observed at age 1 year in TDF-exposed infants are of uncertain significance but underscore the need for additional studies of growth outcomes after TDF use during pregnancy.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Comment in

References

    1. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents – October 14, 2011. [Accessed November 2, 2011.]; http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&Cl....
    1. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States - September 14, 2011. [Accessed November 2, 2011.]; http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=9&Cl.... - PubMed
    1. Tarantal A, Castillo A, Ekert J, Bischofberger N, Martin R. Fetal and Maternal Outcome After Administration of Tenofovir to Gravid Rhesus Monkeys (Macaca mulatta) J Acquir Immune Defic Syndr. 2002;29(3):207. - PubMed
    1. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004 May;48(5):1469–87. - PMC - PubMed
    1. Van Rompay K, Durand-Gasselin L, Brignolo L, Ray A, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics, biological and virological effects. Antimicrob Agents Chemother. 2008;52(9):3144–60. - PMC - PubMed

Publication types

MeSH terms